XENERA-1: A Multi-centre, Double-blind, Placebo-controlled, Randomised Phase II Trial to Compare Efficacy of Xentuzumab in Combination With Everolimus and Exemestane Versus Everolimus and Exemestane in Post-menopausal Women With HR+ / HER2- Metastatic Breast Cancer and Non-visceral Disease
Phase of Trial: Phase II
Latest Information Update: 13 Feb 2019
At a glance
- Drugs Everolimus (Primary) ; Exemestane (Primary) ; Xentuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms XENERA-1
- Sponsors Boehringer Ingelheim
- 08 Jan 2019 Planned number of patients changed from 90 to 80.
- 11 Dec 2018 Status changed from not yet recruiting to recruiting.
- 27 Nov 2018 Planned End Date changed from 3 Jan 2022 to 12 Jan 2022.